Originariamente Scritto da Ponno
Visualizza Messaggio
Luke ultimamente ha imboccato una discesa verso il Lukinismo imbarazzante.
Comunque ieri leggevo che pare il Corona diminuisca l'IQ, considerando che Luke é stato sintomatico e valutando il decorso dei suoi posts potrebbe essere una conferma.
Comunque ieri leggevo che pare il Corona diminuisca l'IQ, considerando che Luke é stato sintomatico e valutando il decorso dei suoi posts potrebbe essere una conferma.
Case studies have revealed neurological problems in severely affected COVID-19 patients. However, there is little information regarding the nature and broader prevalence of cognitive problems post-infection or across the full spread of severity. We analysed cognitive test data from 84,285 Great British Intelligence Test participants who completed a questionnaire regarding suspected and biologically confirmed COVID-19 infection. People who had recovered, including those no longer reporting symptoms, exhibited significant cognitive deficits when controlling for age, gender, education level, income, racial-ethnic group and pre-existing medical disorders. They were of substantial effect size for people who had been hospitalised, but also for mild but biologically confirmed cases who reported no breathing difficulty. Finer grained analyses of performance support the hypothesis that COVID-19 has a multi-system impact on human cognition.
Significance statement There is evidence that COVID-19 may cause long term health changes past acute symptoms, termed ‘long COVID’. Our analyses of detailed cognitive assessment and questionnaire data from tens thousands of datasets, collected in collaboration with BBC2 Horizon, align with the view that there are chronic cognitive consequences of having COVID-19. Individuals who recovered from suspected or confirmed COVID-19 perform worse on cognitive tests in multiple domains than would be expected given their detailed age and demographic profiles. This deficit scales with symptom severity and is evident amongst those without hospital treatment. These results should act as a clarion call for more detailed research investigating the basis of cognitive deficits in people who have survived SARS-COV-2 infection.
### Competing Interest Statement
The authors have declared no competing interest.
### Funding Statement
Dr Hampshire is supported by the UK Dementia Research Institute and Biomedical Research Centre at Imperial College London with technology development supported by EU-CIG EC Marie‐Curie CIG and NIHR grant II-LB-0715-20006. William Trender is supported by the EPSRC Center for Doctoral Training in Neurotechnology. Dr Chamberlains role in this study was funded by a Wellcome Trust Clinical Fellowship (Reference 110049/Z/15/Z). Joseph M Barnby is supported by the UK Medical Research Council (MR/N013700/1) and Kings College London member of the MRC Doctoral Training Partnership in Biomedical Sciences. Mitul Mehta is in part supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and Kings College London. The views expressed are those of the author(s) and not necessarily those of the NHS the NIHR or the Department of Health and Social Care. We would like to acknowledge COST Action CA16207 European Network for Problematic Usage of the Internet supported by COST (European Cooperation in Science and Technology) and the support of the National UK Research Network for Behavioural Addictions (NUK-BA).
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics were approved through Imperial College London Research Ethics Committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data available upon request
Commenta